Lack of enrollment

The purpose of this randomized clinical trial is to determine whether risperidone alone, trazodone alone, or a combination of risperidone and trazodone is superior for the treatment of ICU acquired delirium. The hypothesis is that combination therapy is superior to either agent alone in treating ICU acquired delirium and sustaining delirium free time.

Delirium is defined as a disturbance of consciousness characterized by an acute onset of impaired cognitive function. Although delirium is thought to be common in the Intensive Care Unit (ICU) there are few studies that have evaluated its incidences, risks and outcomes. It has been associated with increased morbidity, and mortality and increased cost to the healthcare system. In addition to the uncertainty of the incidence of ICU delirium, there is a lack of information about the effects that certain pharmacological treatments have on delirious patients.

The rationale for this study is to evaluate the efficacy and safety of risperidone alone, trazodone alone, and risperidone plus trazodone for the treatment of delirium in critically ill patients when compared to placebo.

Inclusion Criteria:

• Age greater than 18 years old who are admitted for more than 24 hours in the MICU or SICU
• Patients diagnosed with delirium by primary team (screened positive for delirium using the CAM-ICU or with clinical manifestations of delirium)
• Patients have an order for as-needed haloperidol or have received a one-time dose of haloperidol within 24 hours of randomization
• Patients must be tolerating enteral feeding (greater than 20 mL/hour for more than 12 hours)

Exclusion Criteria:

• Patients who are unlikely to survive 24 hours after admission to the ICU
• Patients who are admitted with a primary neurological condition or injury (i.e. stroke, active seizures, prolonged coma, overdose)
• Patients who can not actively participate in delirium assessment
• Patients actively withdrawing from alcohol or narcotics
• Patients who were treated with any antipsychotic or trazodone within 30 days prior to ICU admission
• Patients with a marked baseline prolongation of the QTc interval (repeated demonstration of QTc interval greater 500 milliseconds (msec))
• Patients with a history of Torsades de Pointes
• Patients with current treatment with an agent having either the potential to affect or increase the risk of QTc prolongation (e.g. erythromycin, any class Ia, Ic, or III antiarrhythmics)
• Patients being treated with a neuromuscular blocker
• Patients in whom haloperidol, risperidone, or trazodone is contraindicated
• Pregnant patients or patients who are breast-feeding
• Patients with a modified Blessed dementia rating scale score ≥4 or an Informant Questionnaire of Cognitive Dysfunction in the Elderly Score ≥4
• Patients in which informed consent can not be obtained from the legally authorized representative